New Infectious Disease Test Promises Quick Diagnosis
|
By LabMedica International staff writers Posted on 05 Jan 2016 |

Image: Colored Transmission electron micrograph of Clostridium difficile forming an endospore (red) (Photo courtesy of Dr. J. Thomas Lamont).
Early detection of specific pathogens has long been recognized as a vital strategy in the control of infectious diseases because it can lead to timely care of patients and prevent potential outbreaks.
The detection of specific bacteria represents a significant challenge because of the presence of many different species of bacteria in biological samples. Furthermore, for any given species of bacterium, only virulent strains are infectious while other strains of the same species may be harmless or even beneficial to human health.
A team of scientists led by those at McMaster University (Hamilton, ON, Canada) found a way to make DNAzymes, or single-stranded catalytic DNA molecules from a simple test tube technique that allows for isolation of rare DNA sequences with special functions. The team's first success was the development of a molecular probe that precisely recognizes the strain which caused the outbreak of Clostridium difficile infection in Hamilton, Ontario in 2011. This strain was very infectious, resistant to antibiotics and even fatal to some patients. Instead of having to do several different tests to narrow down to a positive identification of the specific strain, the scientists can now quickly pinpoint this superbug using their new molecular probe.
The team obtained an RNA-cleaving fluorogenic DNAzyme (RFD) that can recognize an infectious strain of C. difficile. This DNAzyme not only exhibits no cross-reactivity to other bacterial species, but also is highly strain-selective for C. difficile. The special DNAzyme (catalytic DNA), RFD-CD1, showed exquisite specificity for a pathogenic strain of C. difficile. RFD-CD1 was derived by an in vitro selection approach where a random-sequence DNA library was allowed to react with an unpurified molecular mixture derived from this strain of C. difficile, coupled with a subtractive selection strategy to eliminate cross-reactivities to unintended C. difficile strains and other bacteria species.
Bruno J. Salena, MD, an associate professor of medicine and coauthor of the study, said, “This technology can be extended to the further discovery of other superbug strain-specific pathogens. For example, such technology would prove useful in the identification of hypervirulent or resistant strains, implementation of the most appropriate strain-specific treatments and tracking of outbreaks.” The study was published on December 16, 2015, in the journal Angewandte Chemie International Edition.
Related Links:
McMaster University
The detection of specific bacteria represents a significant challenge because of the presence of many different species of bacteria in biological samples. Furthermore, for any given species of bacterium, only virulent strains are infectious while other strains of the same species may be harmless or even beneficial to human health.
A team of scientists led by those at McMaster University (Hamilton, ON, Canada) found a way to make DNAzymes, or single-stranded catalytic DNA molecules from a simple test tube technique that allows for isolation of rare DNA sequences with special functions. The team's first success was the development of a molecular probe that precisely recognizes the strain which caused the outbreak of Clostridium difficile infection in Hamilton, Ontario in 2011. This strain was very infectious, resistant to antibiotics and even fatal to some patients. Instead of having to do several different tests to narrow down to a positive identification of the specific strain, the scientists can now quickly pinpoint this superbug using their new molecular probe.
The team obtained an RNA-cleaving fluorogenic DNAzyme (RFD) that can recognize an infectious strain of C. difficile. This DNAzyme not only exhibits no cross-reactivity to other bacterial species, but also is highly strain-selective for C. difficile. The special DNAzyme (catalytic DNA), RFD-CD1, showed exquisite specificity for a pathogenic strain of C. difficile. RFD-CD1 was derived by an in vitro selection approach where a random-sequence DNA library was allowed to react with an unpurified molecular mixture derived from this strain of C. difficile, coupled with a subtractive selection strategy to eliminate cross-reactivities to unintended C. difficile strains and other bacteria species.
Bruno J. Salena, MD, an associate professor of medicine and coauthor of the study, said, “This technology can be extended to the further discovery of other superbug strain-specific pathogens. For example, such technology would prove useful in the identification of hypervirulent or resistant strains, implementation of the most appropriate strain-specific treatments and tracking of outbreaks.” The study was published on December 16, 2015, in the journal Angewandte Chemie International Edition.
Related Links:
McMaster University
Latest Technology News
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
Channels
Clinical Chemistry
view channel
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more
Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read moreMolecular Diagnostics
view channel
Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more
Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read moreIndustry
view channel
New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays
Eurobio Scientific (Les Ulis, France) has signed a distribution agreement with Canhelp Genomics (Hangzhou, China) to broaden availability of the Canhelp‑UCa and Canhelp‑Origin assays. The agreement extends... Read more




.jpg)



